BioSpace News Archive

Today, Trevi announced that it concluded enrollment early for its Phase 2 Cough And NALbuphine (CANAL) trial for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) patients following the previously announced statistically significant efficacy results from the interim analysis (N=26).

LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), announced today that it has completed patient enrollment in the PROMISE II pivotal trial of the LimFlow System.

Frequency Therapeutics, Inc. today announced business updates and financial results for the fourth quarter and full year ended December 31, 2021.

PDS Biotechnology Corporation today announced that the National Cancer Institute (NCI) has achieved the intended enrollment objective of 30 patients in the checkpoint inhibitor (CPI).

Ascletis Pharma Inc. announces the business update on its oral double prodrug ASC10 against Coronavirus Disease 2019.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today at HIMSS22 that the latest Philips Capsule Surveillance solution has received 510(k) market clearance from the U.S. Food & Drug Administration (FDA), paving the way for widespread deployment across healthcare systems in the USA.

Mersana Therapeutics, Inc. announced that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Company’s Phase 1 trial of upifitamab rilsodotin at the upcoming Society of Gynecologic Oncology Annual Meeting on Women’s Cancer being held from March 18-21, 2022 in Phoenix, Arizona.

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of March 2022, which is payable on April 15, 2022 to shareholders of record at the close of business on March 31, 2022.

Werewolf Therapeutics, Inc. announced the publication of two abstracts summarizing upcoming poster presentations at the American Association for Cancer Research Annual Meeting.

AbbVie (NYSE: ABBV) and Scripps Research, an independent, non-profit biomedical research and drug discovery institute, today announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.